

Title:

Reply: SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents

Authors:

Cong Dai, Zi-yuan Dong, Yi-nuo Wang, Yu-hong Huang, Min Jiang

DOI: 10.17235/reed.2023.9438/2022

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:

Dai Cong , Dong Zi-yuan, Wang Yi-nuo , Huang Yu-hong, Jiang Min. Reply: SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents. Rev Esp Enferm Dig 2023. doi: 10.17235/reed.2023.9438/2022.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CC 9438

Reply: SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents

Cong Dai, Zi-Yuan Dong, Yi-Nuo Wang, Yu-Hong Huang, Min Jiang

Department of Gastroenterology. First Affiliated Hospital. China Medical University.
Shenyang City, Liaoning Province. China

Correspondence: Cong Dai

e-mail: cong dai2006@sohu.com

Conflict of interest: the authors declare no conflict of interest.

Keywords: COVID-19. SARS-CoV-2. Inflammatory bowel disease. Anti-TNF-alpha therapy. Vedolizumab. Ustekinumab.

Dear Editor,

We thank Dr Mungmunpuntipantip et al. for their interest and thoughtful comments on our publication (1). The authors have highlighted several important considerations for the impact of the SARS-CoV-2 vaccination on inflammatory bowel disease (IBD) patients with different biological agents. We fully agree with the author's point of view, and we also point out the limitations in our meta-analysis. For example, some factors such as type of IBD, age, sex, disease activity, severity, type of vaccine (AAV, mRNA, or both), booster dose and previous COVID-19 exposure history can impact the seroconversion and breakthrough infections in IBD patients with the SARS-CoV-2 vaccination. At the same time, these factors mentioned by the author will also affect these results. However, we cannot extract the relevant data from the included studies in our meta-analysis for further analysis. Further studies are necessary to accurately determine the effect of these factors on IBD patients given the SARS-CoV-2 vaccination.

References

1. Dai C, Dong ZY, Wang YN, et al. Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis. Rev Esp Enferm Dig 2022;114. E-pub ahead of print. DOI: 10.17235/reed.2022.9264/2022